DUBLIN, December 31, 2021 / PRNewswire / – The “investigation report on China Docetaxel Market 2021-2025 “report was added to ResearchAndMarkets.com to offer.
According to market research, the sales value of Docetaxel in the Chinese market remained constant from 2016 to 2019. Due to the impact of the COVID-19 epidemic on China of all of the hospital’s diagnostic and treatment services, docetaxel s sales value in the Chinese market decreased 1.112 billion CNY in 2020 a decrease of 16.79% compared to the previous year. The CAGR of the sales value of Docetaxel in the Chinese market from 2016 to 2020 was -3.86%.
Docetaxel, sold under the brand name Taxotere, is a paclitaxel anti-tumor drug used to treat locally advanced or metastatic non-small cell lung cancer. Docetaxel Injection was first developed and manufactured by the French company Rhone Planck Lean (later renamed Aventis, also known as Sanofi-Aventis). It was first approved for marketing by the European Union in 1995 and was used in China in 1996. By 2020 there were several manufacturers in the Chinese docetaxel market.
The analyst expects Docetaxel sales to rise again as the COVID-19 epidemic eases from 2021 to 2025. In addition, 4.57 million new cancer cases were in. diagnosed China in 2020, and the overall incidence of cancer rose about 3.9% annually.
Therefore, sales volume of docetaxel for the treatment of locally advanced or metastatic non-small cell lung cancer will increase with the increase in colon cancer patients and there is room for sales growth. At the same time, docetaxel is safer and more effective compared to similar drugs, and sales volume will grow in the future.
The effects of COVID-19 on China Docetaxel market
Sales value of China Docetaxel 2016-2020
Competitive landscape of China Docetaxel market
Prices for Docetaxel in China
Prices for Docetaxel in China by region and manufacturer
Analysis of factors influencing the development of China Docetaxel market
outlook China Docetaxel Market from 2021-2025
Key topics covered:
1 Relevant Concepts of Docetaxel
1.1 Indications for Docetaxel®
1.2 Development of Docetaxel in China
1.3 State approval of Docetaxel in China
1.4 The Effects of COVID-19 on Docetaxel Sales in China
2 Sale of Docetaxel in China, 2016-2020
2.1 Sales value of Docetaxel
2.1.1 Total Sales Value
2.1.2 Sales Value by Region
2.2 Docetaxel sales volume
2.2.1 Total Sales Volume
2.2.2 Sales volume by region
2.3 Sale of Docetaxel by dosage form in China, 2016-2020
2.3.2 Analysis of other dosage forms
3 Analysis of the most important docetaxel manufacturers in China in 2020
3.1 Analysis of the market share of the most important docetaxel manufacturers
3.1.1 Analysis of market share by sales value
3.1.2 Analysis of market shares by sales volume
3.2 Aventis Pharma SA
3.2.1 Company profile
3.2.2 Sale of TAXOTERE (Docetaxel from Aventis Pharma SA) in China
3.3 Jiangsu Hengrui Medicine Co., Ltd.
3.3.1 Company profile
3.3.2 Sale of Aisu (Docetaxel from Jiangsu Hengrui Medicine Co., Ltd.) in China
3.4 Shenzhen-Wanle Pharmaceutical Co., Ltd.
3.4.1 Company profile
3.4.2 Sales by Xichun (Shenzhen Wanle Pharmaceutical Co., Ltd.’s Docetaxel) in China
3.5 Sichuan Huiyu Pharmaceutical Co., Ltd.
3.5.1 Company profile
3.5.2 Sales of Huiyu (Docetaxel by Sichuan Huiyu Pharmaceutical Co., Ltd.) in China
3.6 Yangtze River Pharmaceutical Group Co., Ltd.
3.6.1 Company profile
3.6.2 Sales by Tianlun (Yangtze River Pharmaceutical Group Co., Ltd.’s Docetaxel) in China
4 prices of docetaxel for different manufacturers in China, 2020-2021
4.1 Aventis Pharma SA (TAXOTERE)
4.2 Jiangsu Hengrui Medicine Co., Ltd. (Aisu)
4.3 Shenzhen Wanle Pharmaceutical Co., Ltd. (Xichun)
4.4 Sichuan Huiyu Pharmaceutical Co., Ltd. (Huiyu)
4.5 Yangtze River Pharmaceutical Group Co., Ltd. (Tianlun)
5 China Docetaxel Market Outlook, 2021-2025
5.1 Factors influencing the Chinese market development for docetaxel
5.1.1 The impact of COVID-19 on the Chinese docetaxel market
5.1.2 Market drivers and opportunities
5.1.3 Market Threats and Challenges
5.2 Market size forecast
5.3 Forecast of the market trend
Aventis Pharma SA
Jiangsu Hengrui Medicine Co. Ltd.
Shenzhen Pan Pharmaceutical Co. Ltd.
Sichuan Huiyu Pharmaceutical Co. Ltd.
Yangtze River Pharmaceutical Group Co. Ltd.
Please visit https://www.researchandmarkets.com/r/m41aty for more information on this report
Research and Markets
Laura wood, Senior manager
For EST office hours, call + 1-917-300-0470. on
For US / CAN toll free call + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900. on
US Fax: 646-607-1907
Fax (outside the US): + 353-1-481-1716
View original content: https://www.prnewswire.com/news-releases/china-docetaxel-market-report-2021-sales-2016-2020-2020-major-manufacturers-prices-2020-2021-future-prospects- 2021 -2025-301452360.html
SOURCE Research and Markets